0001140361-17-008973.txt : 20170224 0001140361-17-008973.hdr.sgml : 20170224 20170224100516 ACCESSION NUMBER: 0001140361-17-008973 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160401 FILED AS OF DATE: 20170224 DATE AS OF CHANGE: 20170224 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Emergent BioSolutions Inc. CENTRAL INDEX KEY: 0001367644 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 141902018 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 PROFESSIONAL DR, SUITE 400 CITY: GAITHERSBURG STATE: MD ZIP: 20879 BUSINESS PHONE: 240-631-3200 MAIL ADDRESS: STREET 1: 400 PROFESSIONAL DR, SUITE 400 CITY: GAITHERSBURG STATE: MD ZIP: 20879 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kramer Robert CENTRAL INDEX KEY: 0001380956 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-33137 FILM NUMBER: 17635133 MAIL ADDRESS: STREET 1: 2273 RESEARCH BLVD, SUITE 400 CITY: ROCKVILLE STATE: MD ZIP: 20850 4/A 1 doc1.xml FORM 4/A X0306 4/A 2016-04-01 2016-04-05 0 0001367644 Emergent BioSolutions Inc. EBS 0001380956 Kramer Robert 400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG MD 20879 0 1 0 0 EVP, Corporate Services Divisi Common Stock 2016-04-01 4 M 0 11531 14.41 A 91607 D Common Stock 2016-04-01 4 S 0 11531 35.49 D 80076 D Common Stock 2016-04-01 4 M 0 3939 14.67 A 84015 D Common Stock 2016-04-01 4 S 0 3939 35.74 D 80076 D Common Stock 2016-04-01 4 M 0 17354 28.09 A 97430 D Common Stock 2016-04-01 4 S 0 17354 35.48 D 80076 D Common Stock 2016-04-01 4 M 0 5503 29.00 A 85579 D Common Stock 2016-04-01 4 S 0 5503 35.66 D 80076 D Common Stock 2016-04-01 4 S 0 445 35.93 D 79631 D Common Stock 2016-04-01 4 S 0 1855 35.80 D 77776 D Common Stock 2016-04-01 4 S 0 2945 35.73 D 74831 D Stock Option 14.41 2016-04-01 4 M 0 11531 0 A 2019-11-04 Common Stock 11531 11531 D Stock Option 14.67 2016-04-01 4 M 0 3939 0 A 2020-03-11 Common Stock 3939 3940 D Stock Option 28.09 2016-04-01 4 M 0 17354 0 A 2021-03-10 Common Stock 17354 34708 D Stock Option 29.00 2016-04-01 4 M 0 5503 0 A 2022-03-09 Common Stock 5503 27514 D These sales were executed pursuant to a 10b5-1 trading plan adopted by the reporting person on February 29, 2016. Consists of an option granted under the company's stock incentive plan on November 5, 2012. Consists of an option granted under the company's stock incentive plan on March 12, 2013. Consists of an option granted under the company's stock incentive plan on March 11, 2014. Consists of an option granted under the company's stock incentive plan on March 10, 2015. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.11 to $36.34, inclusive. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.37 to $36.32, inclusive. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.07 to $36.35, inclusive. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.12 to $36.42, inclusive. Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.91 to $36.00, inclusive. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.50 to $36.13, inclusive. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.50 to $36.32, inclusive. The option vested in three equal installments in November 2013, 2014 and 2015. The option vest in three equal installments in March 2014, 2015 and 2016. The option vest in three equal installments in March 2015, 2016 and 2017. The option vest in three equal installments in March 2016, 2017 and 2018. EXPLANATORY NOTE: The sole purpose of this amendment to the Form 4 is to denote that the execution of all of the sale transactions reported by this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 29, 2016. /s/ Eric Burt, attorney-in-fact 2017-02-24